Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal irinotecan + oxaliplatin + tegafur/gimeracil/oteracil versus gemcitabine + capecitabine as adjuvant therapy after curative resection of pancreatic cancer
CTR20243288Phase 3Active
- Sponsor
- CSPC Ouyi Pharmaceutical
- Start
- Oct 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of nanoliposomal irinotecan, oxaliplatin, tegafur + gimeracil + oteracil, gemcitabine, capecitabine in pancreatic cancer (PC), pancreatic adenocarcinoma (PDAC), sponsored by CSPC Ouyi Pharmaceutical. Started Oct 2024; status: active.
02
Drugs
nanoliposomal irinotecanoxaliplatintegafur + gimeracil + oteracilgemcitabinecapecitabine
03
Conditions
pancreatic cancer (PC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on CTR20243288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243288.